Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18057537 | 0.91 | PARP1 (0.40) | ALDH1A1PARP1KMT2AKDM4EHTT | |
| SCHEMBL18057554 | 0.89 | PARP1 (0.41) | PARP1KMT2AKDM4EHTTNPSR1 | |
| SCHEMBL18057528 | 0.88 | HRH4 (0.35) | PARP1KMT2AKDM4EHRH4 | |
| SCHEMBL18057536 | 0.84 | PARP1 (0.38) | ALDH1A1PARP1KMT2AKDM4EHTT | |
| SCHEMBL18057532 | 0.84 | PARP1 (0.38) | ALDH1A1PARP1KMT2AKDM4EHTT | |
| SCHEMBL18057533 | 0.83 | PARP1 (0.40) | PARP1KMT2AKDM4EHTTNPSR1 | |
| SCHEMBL18057540 | 0.80 | POLR1A (0.41) | ALDH1A1KMT2AKDM4EHTTNPSR1 | |
| SCHEMBL18057520 | 0.79 | HRH4 (0.37) | PARP1KMT2AKDM4EHRH4 | |
| SCHEMBL18057547 | 0.78 | PDE4B (0.38) | PARP1KDM4EHTTNPSR1HRH4 | |
| SCHEMBL18057466 | 0.78 | EZH2 (0.38) | ALDH1A1KMT2AKDM4EHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745403-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-08-18 | — | — | US | disclosed |
| US-10590134-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10442801-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2019-10-15 | — | — | US | disclosed |
| US-9951066-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2018-03-22 | — | — | US | disclosed |
| US-20170334905-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2017-11-23 | — | — | US | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758518-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590134-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | ALDH1A1 3165/4885PARP1 168/4885KMT2A 4232/4885 |
| US-20180079750-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | ALDH1A1 3544/4885PARP1 218/4885KMT2A 4568/4885 |
| US-10745403-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | ALDH1A1 3165/4885PARP1 168/4885KMT2A 4232/4885 |
| US-20170334905-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | ALDH1A1 3544/4885PARP1 218/4885KMT2A 4568/4885 |
| US-20160257678-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | ALDH1A1 3544/4885PARP1 218/4885KMT2A 4568/4885 |
| US-10442801-B2 | Compositions, uses and methods for making them | BAX, CASP3, BCL2 | ALDH1A1 3165/4885PARP1 168/4885KMT2A 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.